9th ISMERAD | Alpha Therapy: New approaches in radionuclide therapy – April 26, 2024

Date: 26/04/2024
NH Gent Belfort, Hoogpoort 63, 9000 Gent
Registration is open now! Click here to register for the event!
Registration deadline is on April 18th, 2024.
Click here to see more information about the event on the SCK CEN website.

The 9th Symposium on Medical Radioisotopes is set to be a pivotal event, offering a comprehensive overview of the current state and future outlook of medical radioisotopes. The symposium aims to provide attendees with invaluable insights into various aspects of this dynamic field.

The event’s objectives are ambitious yet crucial. It seeks to inform participants about the global production prospects of medical radioisotopes in the forthcoming years, emphasizing the importance of addressing challenges in transportation and distribution, including safety, security, transparency, and prompt delivery. Additionally, the symposium endeavors to showcase groundbreaking advancements in radiopharmacy and nuclear medicine, while also introducing new industrial and research initiatives poised to shape the field’s trajectory.

Key highlights of the symposium include an opening talk by Zéna Wimana from HUBruxelles, who will shed light on Lu-177 and its potential in therapy, setting the stage for further discussions. Subsequent sessions will cover a range of topics, including the origin and production challenges of alpha-emitters, logistical concerns such as waste management and transportation, clinical potential and dosimetry studies, and glimpses into the future of medical radioisotopes.

The lineup of esteemed speakers includes experts like Sven Van den Berghe, Matthijs Sevenois, Philippe Dasse, Filip De Vos, Pascal Froment, Hans Van De Maele, Mike Sathekge, Michel Koole, Florian Rosar, and Thierry Stora, each bringing their unique perspectives and insights to the table.

As anticipation mounts for this significant event, attendees can expect to gain invaluable knowledge, foster meaningful connections, and contribute to shaping the future landscape of medical radioisotopes.

The Symposium is intended for:

  • Researchers and professionals active in the subfields of interest;
  • European and Belgian health authorities and regulators;
  • Radioisotope distributors and related transport companies


The 9th Symposium on Medical Radioisotopes intends to:

  • Provide information on the perspectives of the world production of medical radioisotopes during the years to come;
  • Discuss challenges of the transport and distribution processes including safety, security, transparency and prompt delivery;
  • Present breakthroughs in radiopharmacy and nuclear medicine;
  • Introduce new industrial and research initiatives.


  • Session 1: Origin/production of alpha-emitters. Challenges for the future – Overview of the activities
  • Session 2: Logistics (waste management)
  • Session 3: Studies | Clinical Potential | Dosimetry
  • Session 4: The future


09:00    Registration and welcome coffee

09:30    Opening

  • Welcome: Hans Van De Maele, PC Secretary
  • Introduction: Bernard Ponsard, PC Chair
  • Formal Opening: Ignace Lemahieu, RUG

09:45    Opening talk

  • Lu-177 and the perspective of alpha therapy | Zéna Wimana, HUBruxelles

Session 1: Origin/production of alpha-emitters. Challenges for the future – Overview of the activities

  • Ac-225 | Sven Van den Berghe, PanTera
  • At-211 | Matthijs Sevenois, Molecular Imaging & THerapy research group (MITH)
  • Pb-212 | Philippe Dasse, ARTBIO

11:00    Coffee break and poster session

11:30    Session 2: Logistics (waste management)  

  • Centralized radiopharmacies | Filip De Vos, Ghent University, Department of Radiopharmacy
  • Waste Management | Pascal Froment, Be.Sure
  • Drone Logistics – AEGLE project on drone logistics for radiopharmaceuticals | Hans Van De Maele, ORI Consult – AEGLE Drone Services

12:30    Poster session

  • Poster competition

13:00    Lunch

14:00    Plenary talk

  • Activities of HERCA in the frame of medical waste mgmt & logistics – European harmonization | TBC

 Session 3: Studies / Clinical Potential / Dosimetry

  • NTP – Clinical Potential | Mike Sathekge, University of Pretoria
  • Challenges in Dosimetry | Michel Koole,KUL

15:30    Coffee break and poster session

16:00    Session 4: The future

  • Potential of Terbium-161 | Florian Rosar, Nuclear Medicine Physician, Department of Nuclear Medicine, Saarland University
  • PRISMAP: projects/preclinical studies REX on projects | Thierry Stora, CERN

16:45    Poster prize ceremony

  • Traditionally 3 prizes are given for the best posters, respectively 500, 350 and 150 €

17:00    Closing

  • Eric van Walle

17:05        Reception




Call for posters to the researchers in the field

Please submit the abstract(s) (20 to 30 lines, title and authors not included) for peer-review by mail to 

bernard.ponsard@sckcen.be & h.vandemaele@be-wis.com

Indicate clearly who is the principal investigator. 

Deadline: March 31, 2024. 

The abstracts of the accepted posters will be published. Similarly to the previous editions, this time too, three prizes (respectively 500, 350 and 150 €) will be allotted for the best three posters.


€200 – regular parcipants

€ 30 – students

BELNUC Seminar: “The power of Artificial Intelligence in Nuclear Medicine – Join the Learning Session!” June 1st, 2024

Save the date for the next BELNUC Seminar: The power of Artificial Intelligence in Nuclear Medicine – Join the Learning Session!

It will take place on 01/06/2024 at UC Louvain/Saint-Luc.

Registration is now open! – Click here to register now!


08:50 – 09:00




09:00 – 09:30
Key Terminology in AI for NM Dummies
Prof. Jef Vandemeulebroucke, VUB
09:30 – 10:00
From Measured Signals to Images: Potential Applications of AI in the Molecular Imaging Chain
Prof. Georg Schramm, KUL
10:00 – 10:30
Advancements in AI-aided Diagnosis and Prognosis for NM Physicians
– Prof. Dr. Erwin Woff, ULB/Institut Jules Bordet
10:30 – 11:00
Coffee Break
11:00 – 11:30
Potential and Pitfalls of AI for Denoising and System Design in Nuclear Medicine
Prof. Stefaan Vendenberghe, UGhent
11:30 – 12:00
A practical AI clinical project at CHU UCL Namur
– Dr. François Xavier Hanin, CHU UCL NAMUR (Dinant Godinne/Sainte-Elisabeth)
12:00 – 12:30
Presentation of the BELNUC AI Workgroup and Project
Prof. Dr. Erwin Woff & Dr. Jens Debacker & BELNUC AI workgroup members


  • RIZIV/INAMI: application/request submitted – still pending.
  • FANC/AFCN: application/request submitted – still pending.

Slides from Seminar (February 2024)

Slides from BELNUC Seminar (February 2024)


Moderators: Dr Anne Delcourt  Mouscron and Pr Olivier Gheysens UCL Bruxelles

09:00-09:45      Marie Vercruyssen – Hematology HUB

“Lymphoma and Multiple Myeloma in 2024: PET guided management and new treatments –> Download slides

09:45-10:30      Pr. Andrea Gallamini – from Nice

“New metrics of PET scan reading in lymphoma” –> Download slides (available soon)

10:30-11:00      Break

11:00-11:30      Pr. Nadia Withofs – CHU Liège 

“Guideline on the use of  PET/CT in Multiple Myeloma” –> Download slides

11:30-12:30      General assembly

Call for nuclear medicine residents in training: EANM congress 2024 

Format of this session : The ‘expert’ will provide an introductory talk of 15-20 minutes to describe the state of the art referring to existing guidelines. Then, a team of nuclear medicine residents will challenge the expert with questions on this topic supported by real life data, clinical cases or local experience. 

4 Grants : All recipients will receive a complementary EANM congress registration and €1000 travel allowance. 

Eligibility criteria :  

  • Nuclear medicine resident in training (3rd, 4th or 5th year). 
  • Member of BELNUC in order of payment by April 30, 2024.
  • Submit a personal statement/motivation letter. 
  • Submit an interesting and unpublished image with a 150-word abstract. 
  • Submission deadline : Wednesday 15 May 2024 12:00 CET. Application should be sent to office@belnuc.be 

Selection procedure :  

All applicants are invited to present their case on June 1st after the Belnuc seminar (details will follow later). 

Results will be announced by the Belnuc president by email mid June 2024. 

BELNUC LinkedIn account

The BELNUC Association has now upped their Social Media presence by creating a BELNUC LinkedIn account.

Take a look at our LinkedIn profile to keep yourself up-to-date and enjoy some interaction within the BELNUC community!

Click here to get to the BELNUC LinkedIn!

BELNUC 2024 Membership renewal available!

The renewal for the BELNUC 2024 Membership is now available on the myBELNUC platform!

Further information regarding the membership like membership types, membership fees or advantages of being a BELNUC member can be found on our BELNUC Membership page.

Login to your myBELNUC account and renew your membership today to continue to benefit from your BELNUC membership!

BELNUC General Assembly and Seminar: February 24th, 2024

Save the date for the next annual BELNUC General Assembly and Seminar: 24/02/2024 at the KUL campus (9:00 – 12:30).

  • Venue: KUL Leuven, Code Parking 7655#, auditorium GA1 located at Onderwijs & Navorsing 1.

Click here to register!

The annual BELNUC General Assembly and Seminar is kindly supported by Von Gahlen.

Von Gahlen is a state-of-the-art manufacturer of shielding solutions for nuclear medicine and radiopharmacy. We offer standard and custom-built hot cells along with a wide range of auxiliary equipment for hot labs. With Von Gahlen you can be assured of safe solutions, a reliable partnership, and a lasting relationship.

Seminar topic: PET in hematological Malignancies:

The last fifteen years have been marked by the harmonization of interim and end-of-treatment PET/CT interpretation criteria in lymphoma (Deauville scale 2009).

Nowadays, the implementation of PET/CT guided therapeutic strategies and  the development of new prognostic biomarkers on baseline PET/CT, such as total metabolic tumor volume and tumor dissemination metrics are necessary.

It is time to propose standardized measurements of metabolic tumor burden to prepare for risk adaptation in lymphoma.

Likewise, the implications of PET imaging in multiple myeloma for treatment and response assessment will also be detailed.



Moderators: Dr Anne Delcourt  Mouscron and Pr Olivier Gheysens UCL Bruxelles

09:00-09:45      Marie Vercruyssen – Hematology HUB

                        “Lymphoma and Multiple Myeloma in 2024: PET guided management and new treatments”

09:45-10:30      Pr. Andrea Gallamini – from Nice. 

                        “New metrics of PET scan reading in lymphoma”

10:30-11:00      Break

11:00-11:30      Pr. Nadia Withofs – CHU Liège.

                        “Guideline on the use of  PET/CT in Multiple Myeloma”

11:30-12:30      General assembly

  • RIZIV/INAMI has granted 2 credits (Category 3, N°23032711) – RIZIV/INAMI accreditation for nuclear medicine physicians is available for BELNUC members only.
  • FANC/AFCN has granted: 2h pour les médecins nucléaristes, 2h pour les personnes habilitées en médecine nucléair, 2h pour les radiophysiciens en médecine nucléair, 2h pour les radiopharmaciens

Open call for BELNUC Tech Board members

The BELNUC Tech Board is urgently looking for technologists (preferably French speaking) that want to join their enthusiastic team and help shape the future of BELNUC activities.

Are you willing to contribute fresh ideas and assist in the Tech Board activities? Send in your application today using the form below!

Open call tech board

NMN Symposium: Diagnostic and Therapeutic Innovations in the Era of Precision Medicine – Nuclear Medicine Meets Neuro-Oncology

NMN Symposium: Precision Medicine

April 26-27th, 2024 in Vienna, Austria

We would like to inform you that the registration to the first Symposium on „Diagnostic and Therapeutic Innovations in the Era of Precision Medicine – Nuclear Medicine Meets Neuro-Oncology“ to be held on April 26-27th 2024 in Vienna is now open.

Click here to register for the symposium!

You can find all information including the program on our website.

Please note that you can also sign up for our newsletter to receive updates as we approach the meeting.

Open call BELNUC Board members 2024

During the 2024 General Assembly (24/02/2024), the BELNUC members will elect a new board:

– position of President-elect.

– position of General Secretary-elect.

– one regular board members will be open.

– one member position for a physicist will be open.

If you are interested, applications can now be submitted until 7/01/2024!

Click here to apply for a BELNUC board position!